Skip to main content

Table 3 Grades of hypertension resulting as a side effect of cancer therapy per the NCI Common Terminology Criteria for Adverse Events (CTCAE) [39]

From: Etiology and management of hypertension in patients with cancer

Grade of Hypertension Severity
Grade 1
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
Systolic BP 120–139 mmHg or diastolic BP 80–89 mmHg
Grade 2
Moderate; minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental ADL
Systolic BP 140–159 mmHg or diastolic BP 90–99 mmHg;
Recurrent or persistent elevation (>  24 h);
Symptomatic increase by > 20 mmHg (diastolic) or to > 140/90 mmHg if previously WNL;
Monotherapy is indicated
Grade 3
Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL
Systolic BP > 160 mmHg or diastolic BP > 100 mmHg;
Medical intervention is indicated;
Requires more intensive therapy than previously used or more than one drug
Grade 4
Life-threatening consequences; urgent intervention indicated
Life-threatening consequences (malignant hypertension, transient or permanent neurological deficit, hypertensive crisis);
Urgent intervention is indicated
Grade 5
Death related to AE
Death
  1. Adapted from Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Published Nov,2017